Search Medical Condition
Please enter condition
Please choose location

Deep Vein Thrombosis Clinical Trials

A listing of Deep Vein Thrombosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (91) clinical trials

EINSTEIN CHOICE is a phase II study designed to evaluate whether once-daily rivaroxaban in doses of 10mg or 20mg is superior to aspirin for the prevention of symptomatic recurrent DVT and/or PE in patients who have completed between six and 12 months of anticoagulant therapy. The study will include approximately ...

Phase

Evaluation of Soluble Fibrin in Thrombosis Exclusion

Rationale. Pulmonary embolism (PE) is a major public health problem. D-dimer (D-Di) assay is useful to exclude VTE (DVT and PE) but not specific, requiring irradiating and expensive imaging tests. Preliminary results suggest that the Soluble Fibrin (SF) assay has a sensitivity comparable to the D-Di one, but a higher ...

Phase N/A

Utilization of TEG to Monitor Rivaroxaban Activity

Rivaroxaban is a novel factor Xa inhibitor that is widely used for stroke prevention in nonvalvular atrial fibrillation, treatment of venous thromboembolism (VTE), and for VTE prophylaxis in patients undergoing knee or hip replacement surgery. Current standard measurements of coagulation are relatively poor at reliably measuring detecting Rivaroxaban effects and ...

Phase N/A

Angel Catheter Post Market Registry

The Registry population will include all consecutive patients in whom the Angel Catheter is placed at participating sites. Information about the use of the catheter will be collected from placement through three days after device removal, or through death or discharge, whichever occurs first. Date of discharge/transfer from the Critical ...

Phase N/A

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis

Background: Upper extremity deep vein thrombosis (UEDVT) constitutes approximately 10% of all DVT. A recent increase in incidence is largely secondary to the increasing use of peripherally inserted central venous catheters. Treatment for UEDVT is derived from evidence for treatment of lower extremity deep vein thrombosis (LEDVT). No evidence exists ...

Phase

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

Despite the substantial number of work published over the past years in different populations around the world, a fundamental gap remains in understanding whether and how genomic admixture and polymorphisms in warfarin-related pharmacogenes account for the high inter-individual dose variability observed in Caribbean Hispanic patients. In addition to being a ...

Phase N/A

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first time. The occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver ...

Phase N/A

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

The objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors) in the treatment and secondary prevention of VTE in pediatric subjects with regard to the composite efficacy endpoint (ie, symptomatic ...

Phase

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified. Patients with persistent atrial fibrillation (>12 hours) or recurrent sustained atrial fibrillation (>2 episodes of atrial fibrillation lasting longer than 30 minutes) will be candidates for inclusion. Upon ...

Phase

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

Other objectives are to clarify the additional outcomes of: Stroke (Measured by number of incidences) Transient Ischemic Attack (TIA) (Measured by number on incidences) ST Elevated Myocardial Infarction (STEMI) (Measured by number of incidences) Non-ST Elevated Myocardial Infraction (NSTEMI) (Measured by number of incidences) Unstable Angina (Measured by number of ...

Phase N/A